CXCR2 and chronic obstructive pulmonary disease: In a recent clinical study performed by Rennard et al., use of CXCR2 antagonist (MK-7123) in COPD patients has shown a significant neutrophil lowering effect leading to improvements in FEV1 and reductions in exacerbations in active smokers as compared to placebo [185].